CASI Pharmeceuticals

Product Pipeline

CASI’s business goal is to bring high-quality pharmaceuticals to the growing China market.

CASI 2018 Pipeline

EVOMELA® (melphalan) for injection, already marketed in the U.S. by our partner, is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Our import drug registration is currently pending with CFDA with priority review granted.

MARQIBO® (vinCRIStine sulfate LIPOSOME injection), already marketed in the U.S. by our partner, is indicated for the treatment of advanced Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Our import drug registration is currently pending with CFDA.

ZEVALIN® (ibritumomab tiuxetan), also already marketed in the U.S. by our partner, is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL).

We intend to develop these 3 FDA approved drugs for import drug registration in the greater China region. For the most up-to-date safety information about these drugs, please refer to our partner’s website www.sppirx.com and to:

http://www.evomela.com

http://www.marqibo.com

http://www.zevalin.com

ENMD-2076, is our proprietary orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase and is ongoing in one Phase 2 clinical study.

CASI-001 and CASI-002 are proprietary preclinical candidates in immuno-oncology.

CASI will continue to aggressively expand its portfolio through in-licensing and acquisition.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

Poster

Annual Meeting Presentation

Download →

Poster

Corporate Presentation - BIO International Convention

Download →

Poster

Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →